课题基金 / 基金详情

项目摘要

项目成果

HUI-WEN LO的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Epidermal growth factor receptor (EGFR) is critically involved in the genesis and progression of human cancers and is considered as an attractive target for anti-cancer therapy. However, clinical success with anti-EGFR therapy remains limited in part due to our incomplete knowledge of the EGFR pathway. Accumulating evidences revealed a novel mode of EGFR signaling in which EGF ligand shuttles EGFR into the nucleus, leading to cyclin D1 gene activation. Patients with breast tumors that contain high nuclear EGFR survived poorly compared to those with no/low levels. However, the nature and pathological significance of this novel EGFR network remain largely unknown. We will test the hypothesis that nuclear EGFR functions as both a transcriptional regulator and a tyrosine kinase and that de-regulated nuclear EGFR pathway contributes to a more aggressive biology of human tumors. Preminary data indicate a novel nuclear interaction between EGFR and the oncogenic transcription factor, signal transducer and activator of transcription-3, STATS, leading to increased expression of inducible nitric oxide synthase (iNOS). Aim 1 will characterize nuclear EGFR/STAT3 interaction and determine its role in iNOS gene regulation. Moreover, whether nuclear EGFR also functions as a tyrosine kinase remains unknown. Interestingly, preliminary results suggest that nuclear EGFR phosphorylates c-jun. In addition, we found that EGF activates expression of TWIST, a mediator for epithelial-mesenchymal transition (EMT)/metastasis and that TWIST gene promoter can be regulated by EGFR, c-jun and STATS. Aim 2 will thus determine the effect of EGFR/ c-jun/STAT3 interplay on TWIST gene activation and TWIST-mediated EMT/tumor progression. A role of nuclear EGFR in Taxol/5-Fu resistance is suggested by our preliminary data. Aim 3 will determine the significance and mechanisms for nuclear EGFR-mediated chemoresistance. This proposal is highly relevant to public health and its outcome will shed light into the nuclear EGFR signaling network in human cancers.
期刊论文(16)
专著(0)
科研奖励(0)
会议论文
Emerging therapeutic targets and agents for glioblastoma therapy--part II.
胶质母细胞瘤治疗的新兴治疗靶点和药物——第二部分。
DOI: 10.2174/187152010793498672
发表时间: 2010
期刊: Anti-cancer agents in medicinal chemistry
影响因子: 2.8
作者: [Lo,Hui-Wen]
通讯作者: Lo,Hui-Wen
DOI: 10.1016/j.canlet.2012.01.011
发表时间: 2012-05-28
期刊: CANCER LETTERS
影响因子: 9.7
作者: [Han, Woody, Lo, Hui-Wen]
通讯作者: Lo, Hui-Wen
STAT1 gene expression is enhanced by nuclear EGFR and HER2 via cooperation with STAT3.
核EGFR和HER2通过与STAT3的配合增强STAT1基因表达。
DOI: 10.1002/mc.21936
发表时间: 2013-12
期刊: MOLECULAR CARCINOGENESIS
影响因子: 4.6
作者: [Han, Woody, Carpenter, Richard L., Cao, Xinyu, Lo, Hui-Wen]
通讯作者: Lo, Hui-Wen
DOI: 10.1016/j.canlet.2010.01.028
发表时间: 2010-08-01
期刊: CANCER LETTERS
影响因子: 9.7
作者: [Zhu, Hu, Cao, Xinyu, Ali-Osman, Francis, Keir, Stephen, Lo, Hui-Wen]
通讯作者: Lo, Hui-Wen
14
    Roles of tGLI1 and microRNA Network in Breast Cancer Brain Metastasis
    Roles of tGLI1 and microRNA Network in Breast Cancer Brain Metastasis
    Roles of tGLI1 and microRNA Network in Breast Cancer Brain Metastasis
    Roles of tGLI1 and microRNA Network in Breast Cancer Brain Metastasis
    国内基金
    海外基金
    帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
    • 批准号:
      32170319
    • 项目类别:
      面上项目
    • 资助金额:
      58.00万元
    • 批准年份:
      2021
    • 负责人:
      董春海
    • 依托单位:
    帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
    • 批准号:
      --
    • 项目类别:
      --
    • 资助金额:
      58万元
    • 批准年份:
      2021
    • 负责人:
      董春海
    • 依托单位:
    ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
    番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
    • 批准号:
      31372080
    • 项目类别:
      面上项目
    • 资助金额:
      80.0万元
    • 批准年份:
      2013
    • 负责人:
      杨迎伍
    • 依托单位: